Pass RAPS Regulatory Affairs Certification (RAC) US Exam in First Attempt Guaranteed Updated Dump from Actual4Cert!
Pass RAC-US Exam with 100 Questions - Verified By Actual4Cert
The RAC-US exam is an important certification for regulatory professionals who want to demonstrate their expertise in regulatory affairs. RAC-US exam is designed to test the knowledge and skills of regulatory professionals and to ensure that they have a thorough understanding of the regulatory landscape. The RAC-US exam is recognized globally and is a symbol of excellence in the regulatory affairs profession.
NEW QUESTION # 56
A company is currently marketing an implantable orthopedic medical device. The R&D department is planning to change the material used for the implant. The R&D department states that the change does not impact the safety and effectiveness of the product.
What action should the regulatory affairs professional take FIRST?
- A. Prepare regulatory submissions that detail the medical device's change in materials.
- B. Write a memo to file since the change does not impact product safety and effectiveness.
- C. Review the content of change and supporting data for the equivalency with the current material.
- D. No action is needed in this situation.
Answer: C
NEW QUESTION # 57
Why is it necessary to run supplemental safety pharmacology studies?
- A. To substitute the utilization of GLP
- B. To provide adverse reaction reports and the results of the statistical data to the regulatory authority
- C. To comply with regulatory authority requirements related to clinical studies
- D. To evaluate potential adverse pharmacodynamics effects not addressed by the core battery
Answer: D
NEW QUESTION # 58
During routine surveillance, a regulatory authority sent a company the following communication: "Hepatotoxicity and suicidal behavior were identified as potential safety issues for the company's product. The regulatory authority is evaluating these issues to determine the need for any regulatory action." Which action would be the most appropriate
FIRST step for the company to take?
- A. Repeat the Hepatotoxicity tests and send the results to the regulatory authority.
- B. Contact the regulatory authority to discuss its findings.
- C. Wait for the regulatory authority's final publication on its findings.
- D. Contact the regulatory authority to argue that its conclusions are wrong.
Answer: B
NEW QUESTION # 59
Which of the following criteria is MOST appropriate to define the animal species needed for the pre-clinical toxicity testing of a biotechnology product?
- A. Immunochemical and functional tests
- B. Proposed dose and volume of administration
- C. Proposed product route and frequency of administration
- D. Biological activity with species and/or tissue specificity
Answer: D
NEW QUESTION # 60
Under which of the following circumstances would a regulatory authority require a more detailed premarket submission, a more rigorous audit, and/or the provision of more performance evaluation data than would normally apply to an IVD device of that risk class?
- A. The device incorporates well-established technology that is already present in the market.
- B. Internationally recognized standards are available to cover the main aspects of the device and have been used by the manufacturer.
- C. The manufacturer's experience level with the type of IVD medical device is limited.
- D. The device is an updated version of a compliant device from the same manufacturer and contains no substantive change.
Answer: C
NEW QUESTION # 61
After numerous failed attempts to decrease an identified risk in a medical device to an acceptable level, the medical device continues to have unacceptable risks. However, the development team wants to continue development. Which is the BEST recommendation to make in this situation?
- A. Perform another risk-benefit analysis.
- B. Redesign the device.
- C. Add a warning in the IFU.
- D. Discontinue the project.
Answer: B
NEW QUESTION # 62
Which term does NOT describe the same concept as the others?
- A. Subsequent entry biologics
- B. Biosimilars
- C. Follow-on protein products
- D. Monoclonal antibody
Answer: D
NEW QUESTION # 63
During new drug development, a new impurity in the drug substance is detected at a level of 0.12%. The intended maximum daily dose Is less than 2 g/day, and the drug Is known generally not to be toxic.
What should be done in response to identifying the impurity?
- A. Perform both identification and non-clinical qualification studies concurrently.
- B. Perform an identification study, wait until the result is available, and then consider performing a non-clinical qualification study.
- C. Perform either an identification study or a non-clinical qualification study.
- D. Perform a non-clinical qualification study, wait until the result is available, and then consider performing an identification study.
Answer: B
NEW QUESTION # 64
During an audit of a contract manufacturing facility by a potential client, the auditor requested to be left alone in the records room. The records room contains information on all products produced by the contract manufacturer.
Which action is MOST appropriate for the regulatory affairs professional to take?
- A. Allow the auditor accompanied access to the room to retrieve the records.
- B. Allow the auditor access to the room and records due to the current audit.
- C. Deny the auditor access to the room and records due to confidentiality concerns.
- D. Deny the auditor access to the room and retrieve only the requested records.
Answer: A
NEW QUESTION # 65
A clinical study of a drug is completed to support a marketing approval application.
According to ICH, how long should a sponsor retain the clinical study essential documents?
- A. Three years after the last clinical study site was supplied with investigational drugs
- B. For at least two years after the last approval of an application in an ICH region
- C. For a minimum of 10 years after completion of the clinical study
- D. Until the product has been discontinued from marketing in all ICH regions
Answer: B
NEW QUESTION # 66
Which of the following claims would classify an apple as a drug?
- A. "It will whiten teeth."
- B. "It will make you look younger."
- C. "It will satisfy hunger."
- D. "It will prevent colds."
Answer: D
NEW QUESTION # 67
A regulation change is imminent and may require further non-clinical testing on a product currently in Phase III clinical trials. What is the most appropriate action to take FIRST?
- A. Arrange for additional testing of the product at the testing facility.
- B. Inform the company's senior management and arrange an emergency meeting
- C. Obtain a copy of the proposed regulation and analyze the impact.
- D. Consult with the company's legal department regarding options.
Answer: C
NEW QUESTION # 68
Which of the following changes to a drug product is MOST likely to be implemented without prior regulatory authority approval?
- A. Introducing a new analytical method
- B. Strengthening a precaution to the product labeling
- C. Deleting an ingredient of the drug product
- D. Deleting a drug substance
Answer: B
NEW QUESTION # 69
A company is developing a novel drug to combat AIDS. The preliminary results are very promising and include instances of complete remission. The company has been granted patents in multiple countries for the drug. The regulatory affairs professional is asked to prepare a brief report concerning potential problems for marketing of the product worldwide. Which of the following is the MOST important consideration to discuss?
- A. International import and export regulations
- B. Doha Declaration in the TRIPS Agreement
- C. The time frame in which the patent will expire
- D. The stability of the drug in all zone conditions
Answer: D
NEW QUESTION # 70
The regulatory authority in Country X issued a request for a mandatory product recall in
Country X due to serious injuries to patients. This product also is distributed in Country Y.
What should the regulatory affairs professional of the product's manufacturer FIRST do in
Country Y?
- A. Draft a formal letter to customers in Country Y about this recall.
- B. Initiate a mandatory recall of the product in Country Y.
- C. Review alt distribution records and complaints reported in Country Y.
- D. Prepare the legal team in Country Y for possible litigations.
Answer: C
NEW QUESTION # 71
The intermediate manufacturing process was changed during development of a pharmaceutical. The change may impact the API specification. Which functional area is responsible for the final approval of the change?
- A. Production
- B. Regulatory
- C. Analytical
- D. Quality
Answer: D
NEW QUESTION # 72
A regulatory affairs professional is asked to review and update regulatory affairs SOPs.
Which aspect of the SOP Is MOST important to consider?
- A. Scope and level of detail
- B. Revision history
- C. Relevance to regulations
- D. Expiration date
Answer: C
NEW QUESTION # 73
A drug product presents degradation during the manufacturing process. In addition to the amount, what information should be provided FIRST in order to use API overage?
- A. Justification
- B. Formulation
- C. Property
- D. Specification
Answer: A
NEW QUESTION # 74
Company X has a patent for an anti-inflammatory drug that will expire in one year. In order to minimize the effect of the patent expiration, which is the BEST action for the company to take?
- A. Develop a generic version of the drug.
- B. Conduct a Phase III study for a new unrelated indication of the drug.
- C. Explore litigation strategy for patent infringements on the drug.
- D. Develop a better brand-name drug in the same class.
Answer: A
NEW QUESTION # 75
......
Penetration testers simulate RAC-US exam: https://pass4sure.actual4cert.com/RAC-US-pass4sure-vce.html